205 related articles for article (PubMed ID: 36428782)
1. The Impact of Clonal Hierarchy and Heterogeneity on Phenotypic Manifestations of Myelodysplastic Neoplasms.
El Hussein S; Loghavi S
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428782
[TBL] [Abstract][Full Text] [Related]
2. Molecular Drivers of Myelodysplastic Neoplasms (MDS)-Classification and Prognostic Relevance.
Hoff FW; Madanat YF
Cells; 2023 Feb; 12(4):. PubMed ID: 36831294
[TBL] [Abstract][Full Text] [Related]
3. High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes.
Alhan C; Westers TM; Cremers EM; Cali C; Witte BI; Ossenkoppele GJ; van de Loosdrecht AA
Br J Haematol; 2014 Oct; 167(1):100-9. PubMed ID: 24976502
[TBL] [Abstract][Full Text] [Related]
4. Founder and subclonal mutations in myelodysplastic syndromes and related myeloid neoplasms.
Makishima H
Best Pract Res Clin Haematol; 2020 Sep; 33(3):101189. PubMed ID: 33038978
[TBL] [Abstract][Full Text] [Related]
5. Does mutational burden add to other prognostic factors in MDS?
Nazha A
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101098. PubMed ID: 31779975
[TBL] [Abstract][Full Text] [Related]
6. Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register.
Moreno Berggren D; Folkvaljon Y; Engvall M; Sundberg J; Lambe M; Antunovic P; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellström-Lindberg E; Jädersten M; Ejerblad E
Br J Haematol; 2018 Jun; 181(5):614-627. PubMed ID: 29707769
[TBL] [Abstract][Full Text] [Related]
7. A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With
Ma L; Liang B; Hu H; Yang W; Lin S; Cao L; Li K; Kuang Y; Shou L; Jin W; Lan J; Ye X; Le J; Lei H; Fu J; Lin Y; Jiang W; Zheng Z; Jiang S; Fu L; Su C; Yin X; Liu L; Qin J; Jin J; Qian S; Ouyang G; Tong H
Front Oncol; 2022; 12():905490. PubMed ID: 35832562
[TBL] [Abstract][Full Text] [Related]
8. Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms.
Palomo L; Meggendorfer M; Hutter S; Twardziok S; Ademà V; Fuhrmann I; Fuster-Tormo F; Xicoy B; Zamora L; Acha P; Kerr CM; Kern W; Maciejewski JP; Solé F; Haferlach C; Haferlach T
Blood; 2020 Oct; 136(16):1851-1862. PubMed ID: 32573691
[TBL] [Abstract][Full Text] [Related]
9. The multifaceted nature of myelodysplastic syndromes: clinical, molecular, and biological prognostic features.
Greenberg PL
J Natl Compr Canc Netw; 2013 Jul; 11(7):877-84; quiz 885. PubMed ID: 23847221
[TBL] [Abstract][Full Text] [Related]
10. Simplified flow cytometry scoring for diagnosis and prognosis of myelodysplastic symptom.
Guo J; Wang H; Xiong S; Zhang X; Zhang C; Yang D; Zhang J; Zhai Z
Am J Transl Res; 2020; 12(11):7449-7458. PubMed ID: 33312381
[TBL] [Abstract][Full Text] [Related]
11. Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 Mutations.
Venable ER; Chen D; Chen CP; Bessonen KR; Nguyen PL; Oliveira JL; Reichard KK; Hoyer JD; Althoff SD; Roh DJ; Miller MA; Begna K; Patnaik MM; Litzow MR; Al-Kali A; Viswanatha DS; He R
Am J Clin Pathol; 2021 Sep; 156(4):679-690. PubMed ID: 33978189
[TBL] [Abstract][Full Text] [Related]
12. Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index.
van Spronsen MF; Ossenkoppele GJ; Holman R; van de Loosdrecht AA
Eur J Cancer; 2014 Dec; 50(18):3198-205. PubMed ID: 25454415
[TBL] [Abstract][Full Text] [Related]
13. Recurrent Cytogenetic Abnormalities in Myelodysplastic Syndromes.
Wall M
Methods Mol Biol; 2017; 1541():209-222. PubMed ID: 27910026
[TBL] [Abstract][Full Text] [Related]
14. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.
Voso MT; Fenu S; Latagliata R; Buccisano F; Piciocchi A; Aloe-Spiriti MA; Breccia M; Criscuolo M; Andriani A; Mancini S; Niscola P; Naso V; Nobile C; Piccioni AL; D'Andrea M; D'Addosio A; Leone G; Venditti A
J Clin Oncol; 2013 Jul; 31(21):2671-7. PubMed ID: 23796988
[TBL] [Abstract][Full Text] [Related]
15. Multiplex ligation-dependent probe amplification assay identifies additional copy number changes compared with R-band karyotype and provide more accuracy prognostic information in myelodysplastic syndromes.
Wang J; Ai X; Qin T; Xu Z; Zhang Y; Liu J; Li B; Fang L; Zhang H; Pan L; Hu N; Qu S; Cai W; Ru K; Jia Y; Huang G; Xiao Z
Oncotarget; 2017 Jan; 8(1):1603-1612. PubMed ID: 27906673
[TBL] [Abstract][Full Text] [Related]
16. The need for additional genetic markers for myelodysplastic syndrome stratification: what does the future hold for prognostication?
Otrock ZK; Tiu RV; Maciejewski JP; Sekeres MA
Expert Rev Hematol; 2013 Feb; 6(1):59-68. PubMed ID: 23373781
[TBL] [Abstract][Full Text] [Related]
17. Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome.
Hou HA; Tsai CH; Lin CC; Chou WC; Kuo YY; Liu CY; Tseng MH; Peng YL; Liu MC; Liu CW; Liao XW; Lin LI; Yao M; Tang JL; Tien HF
Blood Cancer J; 2018 Apr; 8(4):39. PubMed ID: 29618722
[TBL] [Abstract][Full Text] [Related]
18. Cryptic aberrations may allow more accurate prognostic classification of patients with myelodysplastic syndromes and clonal evolution.
Svobodova K; Lhotska H; Hodanova L; Pavlistova L; Vesela D; Belickova M; Vesela J; Brezinova J; Sarova I; Izakova S; Lizcova L; Siskova M; Jonasova A; Cermak J; Michalova K; Zemanova Z
Genes Chromosomes Cancer; 2020 Jul; 59(7):396-405. PubMed ID: 32170980
[TBL] [Abstract][Full Text] [Related]
19. Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?
Nazha A; Sekeres MA; Gore SD; Zeidan AM
Oncologist; 2015 Sep; 20(9):1069-76. PubMed ID: 26194858
[TBL] [Abstract][Full Text] [Related]
20. Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry.
de Swart L; Smith A; Johnston TW; Haase D; Droste J; Fenaux P; Symeonidis A; Sanz G; Hellström-Lindberg E; Cermák J; Germing U; Stauder R; Georgescu O; MacKenzie M; Malcovati L; Holm MS; Almeida AM; Mądry K; Slama B; Guerci-Bresler A; Sanhes L; Beyne-Rauzy O; Luño E; Bowen D; de Witte T
Br J Haematol; 2015 Aug; 170(3):372-83. PubMed ID: 25907546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]